Serum biomarkers associated with disease stage and pain severity among women with endometriosis in Indonesia

article OA: gold CC0
AI-generated summary by qwen3.7-flash, 2026-08-30

In Indonesian women with endometriosis, serum COX-2 levels correlated significantly with both disease stage and pain severity, while CA-125 correlated only with disease stage, indicating distinct biomarker associations.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by qwen3.7-flash, 2026-08-30 · read from full text

This cross-sectional study evaluated serum levels of cyclooxygenase-2 (COX-2) and cancer antigen 125 (CA-125) in Indonesian women diagnosed with endometriosis to determine their correlation with disease stage and pain severity. The researchers found that CO-2 levels correlated significantly with both the extent of endometriosis according to ASRM classification and the intensity of patient-reported pain, whereas CA-125 correlated only with disease stage. Although both biomarkers were associated with pain in multivariable analysis, CO-2 demonstrated superior discriminative ability for identifying severe cases and high pain scores compared to CA-125. This paper is centrally about endometriosis — specifically investigating serum biomarkers as indicators of disease progression and symptom burden.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Endometriosis is a chronic estrogen-dependent disease characterized by the presence of endometrial-like tissue outside the uterine cavity, resulting in chronic inflammation, recurrent pain, and infertility, and affecting approximately 190 million women worldwide. Chronic inflammation in endometriosis may stimulate overexpression of cyclooxygenase-2 (COX-2), which catalyzes prostaglandin E2 production, whereas cancer antigen 125 (CA-125) is a glycoprotein biomarker released by endometrial and mesothelial cells in response to inflammatory processes. The aim of this study was to analyze the correlations between serum COX-2 and CA-125 levels and the degree of endometriosis, based on the revised American Society for Reproductive Medicine classification, and between these levels and pain severity, based on the Numeric Rating Scale. A cross-sectional study was conducted among patients with endometriosis at Dr. Zainoel Abidin Hospital, Banda Aceh, Indonesia. The levels of COX-2 and CA-125 were measured using enzyme-linked immunosorbent assay and chemiluminescence immunoassay, respectively. Spearman correlation and ordinal logistic regression were used for statistical analysis. The median age of the participants was 36 years (range: 19-51 years), and most patients had Stage IV endometriosis (78.6%). COX-2 showed a significant positive correlation with both the degree of endometriosis (r=0.526; p<0.001) and pain severity score (r=0.769; p<0.001). CA-125 also showed a significant positive correlation with the degree of endometriosis (r=0.433; p=0.004), but not with pain severity (r=0.256; p=0.102). Receiver operating characteristic curve analysis showed that COX-2 had good discriminative ability for severe endometriosis (AUC=0.865) and for severe pain (AUC=0.864). In the multivariable model, COX-2 and CA-125 were also significantly associated with pain severity. These findings suggest that COX-2 was more strongly associated with pain severity, whereas CA-125 was more closely related to the degree of endometriosis. Further studies with larger sample sizes and prospective designs are needed to validate these findings and clarify the clinical utility of these biomarkers in endometriosis management.
Full text 2,757 characters · extracted from oa-html · click to expand
Serum biomarkers associated with disease stage and pain severity among women with endometriosis in Indonesia DOI: https://doi.org/10.52225/narra.v6i2.3082Keywords: Endometriosis, endometriosis stage, pain severity, cyclooxygenase-2, CA-125Abstract Endometriosis is a chronic estrogen-dependent disease characterized by the presence of endometrial-like tissue outside the uterine cavity, resulting in chronic inflammation, recurrent pain, and infertility, and affecting approximately 190 million women worldwide. Chronic inflammation in endometriosis may stimulate overexpression of cyclooxygenase-2 (COX-2), which catalyzes prostaglandin E2 production, whereas cancer antigen 125 (CA-125) is a glycoprotein biomarker released by endometrial and mesothelial cells in response to inflammatory processes. The aim of this study was to analyze the correlations between serum COX-2 and CA-125 levels and the degree of endometriosis, based on the revised American Society for Reproductive Medicine classification, and between these levels and pain severity, based on the Numeric Rating Scale. A cross-sectional study was conducted among patients with endometriosis at Dr. Zainoel Abidin Hospital, Banda Aceh, Indonesia. The levels of COX-2 and CA-125 were measured using enzyme-linked immunosorbent assay and chemiluminescence immunoassay, respectively. Spearman correlation and ordinal logistic regression were used for statistical analysis. The median age of the participants was 36 years (range: 19-51 years), and most patients had Stage IV endometriosis (78.6%). COX-2 showed a significant positive correlation with both the degree of endometriosis (r=0.526; p<0.001) and pain severity score (r=0.769; p<0.001). CA-125 also showed a significant positive correlation with the degree of endometriosis (r=0.433; p=0.004), but not with pain severity (r=0.256; p=0.102). Receiver operating characteristic curve analysis showed that COX-2 had good discriminative ability for severe endometriosis (AUC=0.865) and for severe pain (AUC=0.864). In the multivariable model, COX-2 and CA-125 were also significantly associated with pain severity. These findings suggest that COX-2 was more strongly associated with pain severity, whereas CA-125 was more closely related to the degree of endometriosis. Further studies with larger sample sizes and prospective designs are needed to validate these findings and clarify the clinical utility of these biomarkers in endometriosis management. Downloads Downloads Published How to Cite Issue Section License Copyright (c) 2026 Mustaqin Mustaqin, Rajuddin Rajuddin, Tgk. Puspa Dewi, Cut M. Yeni, Rusnaidi Rusnaidi, Rachmad Suhanda This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-html

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosisinfertility

MeSH descriptors

CA-125 Antigen CA-125 Antigen CA-125 Antigen CA-125 Antigen CA-125 Antigen CA-125 Antigen CA-125 Antigen CA-125 Antigen CA-125 Antigen CA-125 Antigen CA-125 Antigen CA-125 Antigen Cyclooxygenase 2 Cyclooxygenase 2 Cyclooxygenase 2 Cyclooxygenase 2 Cyclooxygenase 2 Cyclooxygenase 2 Cyclooxygenase 2 Cyclooxygenase 2

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2026) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

SciLite annotations

chemicals 3
estrogen prostaglandin e2 glycoprotein

Source provenance

europepmc
last seen: 2026-09-21T06:08:07.822426+00:00
openalex
last seen: 2026-08-20T06:06:58.202835+00:00
pubmed
last seen: 2026-09-21T06:02:43.170368+00:00
scilite
last seen: 2026-09-13T09:58:29.948030+00:00
License: CC0 · commercial use OK